Glenmark gets FDA nod for generic fungal skin infections cream
Glenmark Pharma has received final approval from the US health regulator for its cream used for treatment of fungal skin infections.09-11-2015
09-11-2015
Glenmark Pharmaceuticals receives ANDA approval for Clotrimazole and Betamethasone Dipropionate Cream USP, 1% | 0.05%
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated November 09, 2015 titled "Glenmark Pharmaceuticals receives ANDA approval for Clotrimazole and Betamethasone Dipropionate Cream USP, 1% | 0.05%".09-11-2015
Glenmark Pharmaceuticals receives tentative ANDA approval for Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated , titled "Glenmark Pharmaceuticals receives tentative ANDA approval for Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg".30-10-2015
Glenmark Pharmaceuticals Q2 profit rises 20% to Rs198 crore
Consolidated revenue rose 13.6% to Rs1,909 crore in the September quarter from Rs1,680 crore a year ago29-10-2015
Outcome of Board Meeting
Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 29, 2015, inter alia, considered and approved the following matter subject to the consent of members to be taken through Postal Ballot as per the provisions of the Companies Act, 2013 and Rules thereof:- An enabling resolution for raising of funds for an amount not exceeding USD 500 Mn through issuance of securities including...29-10-2015
Outcome of Board Meeting - Appointment of Director
Glenmark Pharmaceuticals Ltd has informed BSE that at the meeting of the Board of Directors of the Company held on October 29, 2015, Mr. Milind Sarwate has been appointed as an Additional Director of the Company.29-10-2015
Clarifies on News item
With reference to news reported on CNBC TV18 on October 29, 2015 - "Setback For Glenmark: 'Sanofi received license Vatelizumab in 2011 & Sanofi not to Pursue Development Of Vatelizumab Molecule'.", Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of Clarification is enclosed.29-10-2015
Announces Q2 results, Limited Review Report, Results Press Release & Management Discussion and Analysis for the Quarter ended September 30, 2015
Glenmark Pharmaceuticals Ltd has announced the following results for the quarter ended September 30, 2015:The Unaudited Standalone results for the Quarter ended September 30, 2015"The Company has posted a net profit of Rs. 3667.14 million for the quarter ended September 30, 2015 where as the same was at Rs. 1164.27 million for the quarter ended September 30, 2014. Total Income is Rs. 15929.05 million for the quarter ended September...29-10-2015
Clarification sought from Glenmark Pharmaceuticals Ltd
The Exchange has sought clarification from Glenmark Pharmaceuticals Ltd with reference to news reported on CNBC TV18 on October 29, 2015 - "Setback For Glenmark: 'Sanofi received license Vatelizumab in 2011 & Sanofi not to Pursue Development Of Vatelizumab Molecule'."The reply is awaited.29-10-2015
Glenmark to sell GlaxoSmithKlines asthma drug in Europe
Glenmark has entered into an agreement with Poland-based Celon Pharma for selling a generic version of GSKs inhaler drug in Europe23-10-2015